Intervention

Semaglutide (Rybelsus®)

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting3

Common conditions14

Lead sponsors shown6

Clinical trials

8 shown

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIVNCT07221214 · 2026-04-17

Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in PsoriasisNCT07401992 · 2026-01-15

GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving TeplizumabNCT06338553 · 2024-06-12

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular DystrophyNCT07642635 · 2026-09-01

NOT_YET_RECRUITING

Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm HealthNCT07179120 · 2026-05-01

NOT_YET_RECRUITING

Improved Treatment and Monitoring of Alzheimer's DiseaseNCT07135245 · 2026-01-01

NOT_YET_RECRUITING

Oral Semaglutide in Patients With Alzheimer's DiseaseNCT07200622 · 2025-09-25

NOT_YET_RECRUITING

Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese AdultsNCT06827002 · 2023-03-29

ACTIVE_NOT_RECRUITING

Common conditions

Alcohol1 Alzheimer Disease1 Alzheimer Disease (AD)1 Appetite Regulation1 Cardiovascular Disease Prevention1 Diabetes Mellitus - Type 21 Duchenne Muscular Dystrophy (DMD)1 HIV1 Obesity & Overweight1 Obesity and Overweight1 Obesity-related Male Infertility1 Psoriasis (PsO)1 Smoking Cigarette1 Type 1 Diabetes1

Leading sponsors

Vanderbilt University Medical Center3 First Affiliated Hospital of Wenzhou Medical University1 Hospital Universitario Dr. Jose E. Gonzalez1 Imperial College London1 Rune Skovgaard Rasmussen1 University of Yaounde 11

Trial status mix

NOT_YET_RECRUITING4

RECRUITING3

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE26

PHASE12

EARLY_PHASE11

PHASE41

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.